ReviewClinical and experimental medicine2025
Dysregulation of the ubiquitin-proteasome system in von Hippel-Lindau syndrome: molecular insights and clinical perspectives.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
von Hippel-Lindau (VHL) syndrome is an autosomal dominant tumor susceptibility syndrome whose pathogenesis is closely associated with dysfunction of the ubiquitin-proteasome system (UPS). When core UPS components-E1, E2, E3 enzymes, and the proteasome-malfunction, the intracellular protein homeostasis network becomes severely disrupted, thereby driving tumorigenesis. This discovery also opens a novel perspective for addressing the therapeutic challenges of VHL syndrome. This review systematically analyzes the mechanisms of abnormally expressed enzymes within the UPS in VHL syndrome and thoroughly examines the progress in therapeutic strategies targeting various UPS components. It aims to provide a theoretical foundation for understanding the molecular mechanisms of this disease and developing precision treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.